View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Medtronic, plc: Key facts and statistics - LTM October 2025

A summary company profile, detailing Medtronic plc’s business operations and financial highlights.

Abbott Laboratories - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Johnson & Johnson: 1 director

A director at Johnson & Johnson bought 1,250 shares at 206.150USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

Abbott Laboratories: Update following affirmation of Aa3 ratings

Our credit view of this issuer reflects its significant global scale and presence, constrained by its litigation uncertainty with respect to preterm infant formula product lawsuits.

Abbott Laboratories: Key facts and statistics - LTM September 2025

A summary company profile, detailing Abbott Laboratories’ business operations and financial highlights.

Johnson & Johnson - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Medtronic Plc: 1 director

A director at Medtronic Plc sold 30,000 shares at 101.948USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

Moody's Ratings assigns Baa3 rating to Baxter's senior notes; outlook ...

Moody's Ratings (Moody's) assigned a Baa3 rating to the proposed new senior unsecured notes issuance of Baxter International Inc. (Baxter). At the same time, we assigned a (P)Baa3 rating to Baxter's senior unsecured shelf registration. There are no changes to Baxter's existing ratings including the ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...

Baxter International Inc.: Update following downgrade to Baa3

Our credit view of this issuer reflects its elevated financial leverage, with delays in reaching previously stated deleveraging targets.

Moody's Ratings downgrades Baxter to Baa3/P-3; outlook is stable

Moody's Ratings (Moody's) downgraded the ratings of Baxter International Inc. (Baxter) including the senior unsecured ratings to Baa3 from Baa2 and the commercial paper rating to Prime-3 from Prime-2. The outlook is stable. Previously, the ratings were on review for downgrade. This action concludes ...

Boston Scientific Corp: 1 director

A director at Boston Scientific Corp sold 12,891 shares at 98.284USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

Moody's Ratings reviews Baxter's Baa2/P-2 ratings for downgrade

Moody's Ratings (Moody's) placed the ratings of Baxter International Inc. (Baxter) on review for downgrade. The ratings placed on review include the Baa2 senior unsecured ratings and Prime-2 commercial paper rating. Previously, the outlook was negative. The review is prompted by operating pressure...

Johnson & Johnson: Key facts and statistics - LTM June 2025

A summary company profile, detailing Johnson & Johnson’s business operations and financial highlights.

Moody's Ratings says J&J's Ortho separation will modestly reduce scale...

Moody's Ratings (Moody's) said that on 14 October, Johnson & Johnson ("J&J") announced that it intends to separate its Orthopaedics business into an independent company called DePuy Synthes. The separation of the Orthopaedics business, which is part of J&J's medical devices segment ("MedTech") will ...

Abbott Laboratories: 1 director

A director at Abbott Laboratories sold 5,550 shares at 134.551USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

Moody's Ratings affirms Baxter at Baa2; revises outlook to negative fr...

Moody's Ratings (Moody's) affirmed Baxter International Inc.'s (Baxter) ratings, including its Baa2 senior unsecured ratings and Prime-2 commercial paper rating. At the same time, we revised the outlook to negative from stable. The ratings affirmation considers Baxter's good scale and diversity as...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Baxter International Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 17 June 2025 in which we reassessed the appropriateness of the ratings in the con...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch